Japan Medical Dynamic Marketing, Inc. (7600) AI Stock Analysis

• Market Cap: ¥14.91B
• Dividend Yield: 3.12%
• Average Volume (3M): 89.74K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.51
• Revenue Growth: 3.59%
• EPS Growth: -163.08%
• Country: JP
• Employees: 511
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): N/A
• Shares Outstanding: 26,475,880
• 10 Day Avg. Volume: 96,020
• 30 Day Avg. Volume: 89,743
• PEG Ratio: 0.24
• Price to Book (P/B): 0.61
• Price to Sales (P/S): 0.60
• P/FCF Ratio: -29.78
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 58 Neutral
• Price Target: ¥603.00 ▲(23.82% Upside)
• Action: Reiterated Date: 10/29/25
• Date: Action: Reiterated 10/29/25

The overall stock score of 58 reflects the company's stable revenue growth and strong balance sheet, offset by profitability challenges and negative free cash flow. Technical indicators suggest a neutral trend with potential risks of a pullback. Valuation is impacted by negative earnings, but the dividend yield offers some investor appeal.

Positive Factors

Strong balance sheet, low leverage

A strong equity base and conservative leverage give the company long-term financial flexibility to weather industry cycles, fund strategic initiatives, and avoid costly refinancing. Low debt reduces default risk and supports sustained investment in product and distribution capabilities over months.

Stable gross profit margins

Relatively stable gross margins indicate durable product economics and pricing power in core medical-device offerings, supporting capacity to absorb operating cost pressure. Stable gross margins underpin sustainable operating profitability once overheads are controlled.

Adequate cash conversion from operations

Adequate operating cash conversion suggests core operations generate cash relative to reported earnings, which is a durable sign of underlying business cash-generation ability and helps finance working capital and near-term reinvestment even as free cash flow swings.

Negative Factors

Negative net profit margin in 2025

A negative net margin is a structural red flag: it erodes retained earnings, limits internal funding for R&D and commercialization, and raises questions about pricing, cost control, or product mix. Persistent losses would impair capital accumulation and strategic optionality.

Free cash flow turned negative

Negative free cash flow restricts the company's ability to self-fund growth and dividends over time. If sustained, it forces reliance on external financing or equity issuance, increasing financing risk and potentially diluting returns, weakening long-term financial resilience.

Severe EPS contraction

A very large negative EPS growth rate signals earnings volatility or one-off impairment events that reduced profitability. Such swings undermine investor confidence and indicate operational or market issues that could persist absent structural corrective measures.

Japan Medical Dynamic Marketing, Inc. Business Overview & Revenue Model

Company Description

Japan Medical Dynamic Marketing, INC. develops, manufactures, imports, and sells medical devices in Japan and the United States. The company provides trauma devices, including nails, screws, plates, and other products surgically implanted in the fracture site; joint prostheses, which replaces natural joints and restores functions damaged or lost due to disease or injury; spinal fixation devices for the use in spinal instability surgery; and artificial bone fillers for the treatment of bone fractures, tumors, and other defects. It offers its products to medical professionals and hospitals. The company was incorporated in 1973 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Japan Medical Dynamic Marketing, Inc. generates revenue through multiple streams, primarily from the sales of its medical devices and pharmaceuticals to hospitals and clinics. The company partners with various manufacturers to distribute their products, earning a margin on sales. Additionally, it may generate income through service contracts for maintenance and support of its medical equipment. Other revenue streams could include consulting services related to product implementation and training for healthcare professionals. Strategic collaborations with healthcare institutions and participation in government healthcare initiatives further bolster its earnings potential.

Japan Medical Dynamic Marketing, Inc. Financial Statement Overview

Summary

Japan Medical Dynamic Marketing, Inc. shows stable revenue growth but faces challenges with profitability as seen in the negative net income in 2025. The balance sheet remains robust with low leverage, but cash flow management is an area of concern due to negative free cash flow. Continued focus on cost management and improving cash flow will be crucial for future financial health.

Income Statement

The company experienced a moderate revenue growth rate over recent years, with a notable increase from 2024 to 2025. However, the net profit margin turned negative in 2025, indicating profitability challenges. Gross profit margins have remained relatively stable, but declining EBIT and EBITDA margins suggest rising operational costs.

Balance Sheet

The balance sheet shows a strong equity base with a healthy equity ratio, demonstrating financial stability. The debt-to-equity ratio is relatively low, indicating conservative leverage. However, a decrease in stockholders' equity in 2025 could be a concern if it continues.

Cash Flow

Free cash flow has fluctuated, turning negative in 2025, which might impact liquidity. The operating cash flow to net income ratio shows adequate cash conversion, but the negative free cash flow raises concerns about the company's ability to fund operations and growth without external financing.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	24.98B	25.11B	23.18B	21.31B	19.19B	16.74B
Gross Profit	14.46B	15.65B	14.76B	13.99B	12.99B	11.42B
EBITDA	1.03B	1.40B	3.27B	3.35B	4.21B	3.47B
Net Income	-669.47M	-461.80M	1.27B	1.42B	2.14B	1.66B
Balance Sheet
Total Assets	32.22B	33.67B	31.49B	29.43B	27.34B	25.19B
Cash, Cash Equivalents and Short-Term Investments	2.35B	3.18B	2.32B	2.80B	2.59B	2.47B
Total Debt	4.35B	3.29B	1.49B	1.87B	1.85B	3.09B
Total Liabilities	8.25B	8.93B	5.88B	6.14B	5.85B	6.48B
Stockholders Equity	23.96B	24.68B	25.51B	23.16B	21.39B	18.63B
Cash Flow
Free Cash Flow	0.00	-504.10M	302.45M	870.67M	1.53B	1.23B
Operating Cash Flow	0.00	1.05B	2.10B	2.19B	3.11B	2.60B
Investing Cash Flow	0.00	-1.67B	-1.80B	-1.48B	-1.75B	-1.35B
Financing Cash Flow	0.00	1.49B	-840.71M	-514.78M	-1.29B	-1.31B

Japan Medical Dynamic Marketing, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 487.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7600, the sentiment is Positive. The current price of 487 is below the 20-day moving average (MA) of 515.45, below the 50-day MA of 502.18, and below the 200-day MA of 519.27, indicating a bullish trend. The MACD of 22.44 indicates Negative momentum. The RSI at 76.22 is Negative, neither overbought nor oversold. The STOCH value of 78.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:7600.

Japan Medical Dynamic Marketing, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
6678	78 Outperform	¥21.68B	16.98	―	3.02%	-4.36%	-14.92%
5187	72 Outperform	¥11.13B	14.53	―	3.52%	4.97%	-10.07%
7792	71 Outperform	¥13.88B	11.28	―	2.90%	16.37%	29.02%
7963	67 Neutral	¥10.10B	11.43	―	1.89%	9.47%	37.35%
7600	58 Neutral	¥14.91B	-14.57	―	3.12%	3.59%	-163.08%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
7777	48 Neutral	¥69.58B	-640.14	1.45%	―	40.50%	91.59%

Japan Medical Dynamic Marketing, Inc. Corporate Events

Japan Medical Dynamic Marketing Profit Slumps but Dividend Raised Despite Weak Outlook

Japan Medical Dynamic Marketing reported a 2.9% year-on-year decline in net sales to ¥17.9 billion for the nine months ended December 31, 2025, with operating profit dropping 57.9% to ¥518 million and profit attributable to owners of parent falling 67.3% to ¥287 million, reflecting a significant contraction in earnings despite relatively stable assets and a high equity ratio of 72.9%. While the balance sheet remained solid and equity increased slightly, the company expects continued profit pressure for the full year to March 31, 2026, forecasting a further sharp decline in operating and ordinary profit, even as it plans to raise its annual dividend from ¥15 to ¥17 per share, signaling management’s intent to maintain shareholder returns despite weaker profitability.

The most recent analyst rating on (JP:7600) stock is a Hold with a Yen527.00 price target. To see the full list of analyst forecasts on Japan Medical Dynamic Marketing, Inc. stock, see the JP:7600 Stock Forecast page.